Prior studies have demonstrated that soluble CD163 (sCD163) levels rise progressively with PD severity and correlate with markers of neuroinflammation and neurodegeneration, further supporting the role of CD163 as a dynamic indicator of monocyte activation and disease progression (43). The gene discussed is CD163; the disease is Parkinson disease.